Thermo Fisher Scientific to Invest $150 Million to Expand Pharma Services Capabilities

Mar. 18, 2019
Expansion projects will increase capacity to meet growing customer demand for biologics

WALTHAM, Mass., March 18, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it is investing $150 million in its Pharma Services business to provide additional capacity for sterile liquid and lyophilized product development and commercial manufacturing.

Included in the site expansion projects are Monza and Ferentino, Italy, and Greenville, North Carolina. In response to customer requests, each of the sites will be equipped with aseptic filling lines and isolator technology. Construction is expected to be completed within the next 24 months.

"These investments will help expand our global sterile manufacturing network and meet the increasing demand from customers that rely on our biologics development and manufacturing expertise," said Michel Lagarde, president of pharma services for Thermo Fisher Scientific. "We continue to invest to expand our capabilities and help our customers deliver the highest quality medicines to the patients who need them."

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

Media Contact Information:

Investor Contact Information:

Ron O'Brien 

Ken Apicerno

Phone: 781-622-1242 

Phone: 781-622-1294

E-mail: ron.obrien@thermofisher.com  

E-mail: ken.apicerno@thermofisher.com

Website: www.thermofisher.com


 

Cision View original content:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-invest-150-million-to-expand-pharma-services-capabilities-300813791.html

SOURCE Thermo Fisher Scientific

Thermo Fisher Scientific At a Glance

More than $24 billion in annual revenue and

70,000 Employees

Premier Brands

– Thermo Scientific

– Applied Biosystems

– Invitrogen

– Fisher Scientific

– Unity Lab Services

Read more

NYSE: TMO (Common Stock)Aug 16, 2019 04:01 PM

Exchange NYSE (US Dollar)NYSE

Price 276.15

Change +2.84  (+1.04%)

Volume 1,035,052

% Change

Intraday High 277.35

52 Week High 305.45

Intraday Low 274.25

52 Week Low 208.34

Today's Open 276.59

Previous Close 273.31

Minimum 20 minute delay

Investor Relations Kit

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit http://www.thermofisher.com.

The world leader in serving science